NEJM at ESMO - Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. Rubin EJ, Yeku OO, Morrissey S. N Engl J Med 2024 Sep 15. doi: 10.1056/NEJMe2411489.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rubin EJ, Yeku OO, Morrissey S. NEJM at ESMO - Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. N Engl J Med 2024 Sep 15. doi: 10.1056/NEJMe2411489.
PMID: 39282920